Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis

New England Journal of Medicine

Volumn 370, Issue 22, 2014, Pages 2093-2101

  Martinez, Fernando J ^a,b   De Andrade, Joao A ^c   Anstrom, Kevin J ^d   King Jr , Talmadge E ^e   Raghu, Ganesh ^f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FUNCTIONAL DISEASE; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ACETYLCYSTEINE; AGED; AZATHIOPRINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDNISONE; TREATMENT FAILURE; VITAL CAPACITY;

EID: 84901746607     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1401739     Document Type: Article

References (12)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Peikert T, Daniels CE, Beebe TJ, Meyer KC, Ryu JH. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 2008;102:1342-8.
3. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42. (Pubitemid 41697286)
4. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
5. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304. [Erratum, Am Respir Crit Care Med 2002;166:426.]
6. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-9. (Pubitemid 36408161)
7. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2:105-10. (Pubitemid 40776230)
8. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304.
9. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43. (Pubitemid 47503070)
10. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, non-compliance, and stratification. Biometrics 1986;42:507-19.
11. Rochon J. Application of GEE procedures for sample size calculations in repeated measures experiments. Stat Med 1998;17:1643-58. (Pubitemid 28367844)
12. Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 1999;20:408-22. (Pubitemid 29460918)